Medicare GLP-1 Bridge: How It Works

For years the answer to “does Medicare cover Wegovy for weight loss?” was a flat no, because federal law bars Part D from covering drugs used for weight loss. Since July 1, 2026, there is a limited exception: a CMS demonstration called the Medicare GLP-1 Bridge.

It is genuinely useful and genuinely strange. It is not Part D. It has its own eligibility rules, its own covered-product list, its own claim path, and no appeals. This article explains exactly how it works, in the order things actually happen. It is not medical advice. Where it describes how a medicine is used, it is summarizing FDA-approved labeling and Instructions for Use; follow your own prescription and your prescriber’s directions.

What is the Bridge?

The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that provides eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026 and December 31, 2027 [1]. It operates outside the Part D benefit’s coverage and payment flow: Part D sponsors carry no risk for these drugs and do not have to opt in for eligible beneficiaries to get them. In 2026 CMS uses a single central processor to handle prior authorization, claims adjudication and pharmacy payment [1].

It was originally scheduled to end December 31, 2026. CMS extended it through the end of 2027 because the BALANCE model did not launch in Part D in 2027, and the extension lets CMS collect more GLP-1 utilization data to share with Part D plan sponsors ahead of any later BALANCE implementation [1][6].

The cost to the beneficiary is a flat $50 copayment (verified 2026-09-14) for a one-month supply, defined as either 28 or 30 days depending on the drug [5]. CMS states it plainly: “Eligible beneficiaries will have a $50 copay.” It is a government-set copay, not a manufacturer savings-card tier and not a cash price, and it is the same for everyone who qualifies — including people with Extra Help.

Who is eligible?

Eligibility has three layers, and you need all three.

Layer one: an eligible plan type

You must be enrolled in a standalone Medicare prescription drug plan (PDP), or a Medicare Advantage coordinated care plan with drug coverage (MA-PD) — meaning an HMO, HMO-POS, or Local or Regional PPO — in CY 2026. Special Needs Plans, employer or union group waiver plans (EGWPs) and the Limited Income Newly Eligible Transition (LI NET) program are all eligible. Dually eligible beneficiaries in an eligible plan type who meet the criteria can also participate [1][5].

Not eligible unless they also have a standalone PDP: private fee-for-service plans, section 1876 cost contract plans, section 1833 health care prepayment plans, PACE organizations, fallback plans and religious fraternal benefit plans [1].

CMS is careful to note that the Bridge is a Section 402 demonstration and is not itself a Part D plan. If you need drug coverage generally, call 1-800-MEDICARE or your local State Health Insurance Assistance Program [1].

Layer two: the reason for the prescription

The drug must be prescribed solely to reduce excess body weight and maintain weight reduction, in combination with current and ongoing lifestyle modification including structured nutrition and physical activity consistent with the FDA-approved label [1].

This is the layer that surprises people. If you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced fibrosis, you are not eligible for the Bridge even if you meet every other criterion — because Part D already covers GLP-1s for those diagnoses. You should get the drug through your Part D plan instead [1][5].

Cardiovascular risk reduction is the trickiest overlap. CMS acknowledges it directly: the Bridge prior authorization does not require the prescriber to attest that you do not have established cardiovascular disease, but it does require attestation that the drug is being prescribed to reduce excess weight and maintain weight reduction. If the drug is being prescribed to reduce the risk of major adverse cardiovascular events — regardless of whether it is also prescribed for weight — that prescription should be routed to your Part D plan [1].

Layer three: the clinical criteria

You must be 18 or older and have met one of three routes at the time you initiated GLP-1 therapy [1][5]:

1. BMI of 35 or higher. No other diagnosis required.
2. BMI of 30 or higher with at least one of: heart failure with preserved ejection fraction (diastolic heart failure); uncontrolled hypertension, defined as systolic blood pressure above 140 mm Hg or diastolic above 90 mm Hg despite concurrent treatment with two antihypertensive medications; or chronic kidney disease stage 3a or above.
3. BMI of 27 or higher with at least one of: prediabetes as defined by American Diabetes Association guidelines; previous myocardial infarction; previous stroke; or symptomatic peripheral artery disease.

The timing rule is the most important detail here. Eligibility is measured at therapy initiation, not at the time of the request — including for people who started before enrolling in Part D and for people who started before July 1, 2026. CMS gives a worked example: a beneficiary who began therapy in September 2024 at a BMI of 37 and has a BMI of 34 in July 2026 qualifies, and the prescriber attests that the BMI 35 criterion was met at initiation [1].

That is genuinely good news for anyone who lost weight and then lost coverage.

Which drugs and devices are covered?

As of the April 6, 2026 update, eligible drugs are [1][4][5]:

• Foundayo (orforglipron) — the oral tablet, the only form in which it is approved. The FDA approved Foundayo for chronic weight management on April 1, 2026 [12][13].
• Wegovy (semaglutide) — injection and tablets. Novo’s Wegovy franchise now spans the 1.7 mg and 2.4 mg injections, the 25 mg tablet approved in December 2025, and Wegovy HD 7.2 mg, approved March 19, 2026 [14].
• Zepbound (tirzepatide) KwikPen only.

The single-dose Zepbound pen and Zepbound vials are not covered [1][4]. CMS publishes the exact National Drug Codes for each eligible product, and notes the list may be updated during the demonstration [1].

Two practical consequences. If you are currently using Zepbound single-dose pens, the Bridge will not pay for them — its covered NDC list includes only the KwikPen. Whether to change device, and how, is a decision for you and your prescriber; the KwikPen has its own FDA-approved Instructions for Use, which differ from the single-dose pen’s. And pen needles for the KwikPen are not covered by the Bridge and should not be billed to it or to your Part D plan; you buy those separately [1].

How does the process actually work?

There is no enrollment form for the beneficiary. The sequence is specific, and getting it out of order produces an error message that wastes a week.

1. Your provider determines you may be eligible and writes a prescription for a covered product.
2. The prescription goes to the pharmacy first. CMS recommends the prescriber include the diagnosis code and an annotation directing the pharmacy to the Bridge to help route it, though neither is required for a claim to process [1]. No Part D denial is required first — if the prescriber has determined you might be eligible, they may direct the pharmacist to send the claim directly to the Bridge [1].
3. The pharmacy submits the claim to the Bridge, which establishes eligibility, and then determines whether prior authorization is needed.
4. The pharmacy transmits the prior authorization request to the prescriber, electronically or by fax, typically within 24 to 72 hours. If the prescriber has not received a request after 72 hours, they can download the fax form from CMS and submit it themselves [1].
5. The prescriber completes and submits the form. Prior authorization is accepted electronically or by fax; CMS strongly encourages electronic submission [1]. The prescriber attests, under penalty of perjury, that the information is accurate and complete, and CMS may independently verify facts such as whether a patient has type 2 diabetes by checking Medicare data [1].
6. The decision is mailed to you and sent to the prescriber through the ePA portal or by fax within 72 hours of submission [1]. You get a letter confirming coverage [5].
7. You pay $50 at the pharmacy for a one-month supply.

The critical sequencing rule: the prescriber should not submit the prior authorization before the pharmacy claim exists. CMS states that attempting to do so returns an error of “patient not found” [1]. Your provider’s office may be used to submitting prior authorization first for commercial plans; this is backwards from that.

One more detail: once approved, your prior authorization is valid — including for refills and dose changes — through December 31, 2027, unless you change to a different GLP-1 [5]. That is far longer than typical commercial authorizations, which run 5 or 6 months.

The Bridge call center for prescribers is 855-273-0102, Monday to Friday, 8am to 7pm Eastern [1]. Beneficiaries can call 1-800-MEDICARE with questions about eligibility or prior authorization status [5].

What does the $50 copay count toward?

Nothing, and this is the part most worth understanding before you decide.

Because the Bridge sits outside Part D, Medicare.gov states that the $50 copayment [5]:

• does not count toward your yearly Part D deductible or out-of-pocket limit;
• does not appear on your Part D Explanation of Benefits;
• does not appear on any Medicare Summary Notice;
• cannot be lowered by Extra Help, the low-income subsidy that helps with Part D costs; and
• cannot be spread across months using the Medicare Prescription Payment Plan.

For 2026 the Part D annual out-of-pocket maximum is $2,100 (verified 2026-09-14 on Medicare.gov) [10]. For someone with high drug costs who would otherwise hit that cap, $50 a month through the Bridge is $600 a year that sits entirely outside it. For someone whose only significant drug is the GLP-1, $50 a month is plainly better than what Part D would have charged if it covered the drug at all.

Medicare.gov adds a related warning that applies to cash alternatives: discount cards such as TrumpRx are not creditable coverage, and using them instead of your Medicare plan means the spending does not count toward your deductible or out-of-pocket maximum either [5].

What if I am denied?

There is no appeals process under the Medicare GLP-1 Bridge. CMS states that a prescriber may resubmit the prior authorization form if they initially entered incorrect information or have updated or additional information to include [1]. A CMS official confirmed this on the record in September 2026: beneficiaries have appeal rights only for GLP-1 coverage decisions issued under the Part D benefit, not for a Bridge denial [15]. (updated 2026-09-14)

In practice that means a denial is usually a documentation problem to fix rather than a decision to contest. Work with your prescriber’s office to identify which attestation failed. Common causes are attesting to current BMI rather than BMI at initiation, routing a prescription for a Part D-covered indication to the Bridge, or prescribing a Zepbound form that is not covered.

If you have a Part D-covered indication, you do have full appeal rights — but through your Part D plan, not the Bridge. Medicare drug plans have five appeal levels: redetermination by the plan, reconsideration by an independent review entity, an administrative law judge hearing, Medicare Appeals Council review, and federal district court [11].

How does this compare with my other options?

Part D, if another indication applies. If you have type 2 diabetes, obstructive sleep apnea or MASH, your GLP-1 goes through Part D, where normal cost sharing applies, the $2,100 out-of-pocket cap applies, Extra Help can reduce your costs, the Medicare Prescription Payment Plan can spread them across the year [8][9], and you have full appeal rights. Whether one of those diagnoses applies to you is a clinical question for your provider.

Manufacturer savings cards. Not available. Copay cards exclude anyone with Medicare.

Patient assistance programs. Possible for some people with Medicare, subject to income limits and denial-letter requirements. Novo Nordisk’s program accepts Medicare beneficiaries who meet income tests, though it removed Ozempic from availability for Medicare beneficiaries with drug coverage for 2026 — and Wegovy did not appear on the program’s published covered-product page when we checked it on September 14, 2026.

Cash purchase. Available, but nothing counts toward Medicare accumulators.

What happens after 2027?

The Bridge is scheduled to end December 31, 2027. The BALANCE model — a five-year CMS Innovation Center model announced in December 2025 that would negotiate lower GLP-1 prices and set standardized coverage criteria with lifestyle supports — was planned for Part D implementation in January 2027 but has been delayed, which is why the Bridge was extended [6][7].

There is no guarantee about what follows. If you are relying on the Bridge, watch for CMS announcements during 2027 and talk with your provider well before the end date about what continuing care would look like.

Sources

1. Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge — Information for Providers, page last modified August 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
2. Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
3. Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge — Information for Pharmacies. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies
4. Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge: Information for Prescribers (CMS Product No. 12235), June 2026. https://www.cms.gov/files/document/glp-1-prescribers-c-1.pdf
5. Medicare.gov, Weight loss drugs. https://www.medicare.gov/coverage/weight-loss-drugs
6. KFF, What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid
7. Medicare Rights Center, GLP-1 Weight-Loss Drug Demonstration Begins July 2026. https://www.medicarerights.org/medicare-watch/2026/06/04/glp-1-weight-loss-drug-demonstration-begins-july-2026
8. Centers for Medicare & Medicaid Services, Medicare Prescription Payment Plan. https://www.cms.gov/medicare/health-drug-plans/medicare-prescription-payment-plan
9. Medicare.gov, What’s the Medicare Prescription Payment Plan? (fact sheet). https://www.medicare.gov/publications/12211-whats-the-medicare-prescription-payment-plan.pdf
10. Medicare.gov, How much does Medicare drug coverage cost? https://www.medicare.gov/health-drug-plans/part-d/basics/costs
11. Medicare.gov, Appeals in a Medicare drug plan. https://www.medicare.gov/providers-services/claims-appeals-complaints/appeals/drug-plans
12. US Food and Drug Administration, Novel Drug Approvals for 2026. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
13. Eli Lilly and Company, FDA approves Lilly’s Foundayo (orforglipron), April 1, 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
14. Novo Nordisk, FDA approves Novo Nordisk’s new Wegovy HD injection, March 19, 2026. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-new-wegovy-hd-injection-delivering-the-highest-weight-loss-to-date-for-a-wegovy-injection-adding-to-its-already-expansive-clinical-profile-302718982.html
15. AARP, Medicare GLP-1 Bridge program eligibility (CMS confirmation that there is no formal Bridge appeals process), September 2026. https://www.aarp.org/medicare/medicare-glp1-bridge-program-eligibility